Amedica Corporation, a Salt Lake City company that commercializes silicon nitride ceramics as a biomaterial platform, has signed a private label supply agreement with a firm in the People’s Republic of China. The company is BoTEC Medical, a subsidiary of WinnTi Medical Group. Amedica will supply BoTEC Medical with proprietary silicon nitride spinal interbody fusion devices for sale to their worldwide markets.
Amedica Signs Supply Agreement With China Firm
1 min read Premium comments
Secondary
Amedica is focused on the development and application of interbody implants manufactured with medical-grade silicon nitride ceramic. The company’s spine products are FDA-cleared, CE-marked, and are currently marketed in the U.S. and in Europe and South America.
WinnTi Medical was founded by a group of senior executives from leading orthopedic companies in China. BoTEC Medical focuses on innovative extremity and spine solutions.
“This strategic alliance further validates the market adoption of our medical-grade silicon nitride technology platform internationally, ” said Amedica Chairman and CEO Sonny Bal, M.D. “Since launching our second generation silicon nitride interbody fusion devices in 2014, we have been pursuing a multi-channel approach to provide broader accessibility to our proprietary silicon nitride biomaterial. We are very pleased to partner with BoTEC Medical’s team and look forward to participating in their exciting future as they continue to capture additional market share within and outside one of the fastest growing medical device markets in the world.”
“We are very pleased to enter into this partnership with Amedica, as they have a biomaterial platform that will provide BoTEC Medical interbody solutions with a unique value proposition in a highly competitive market, ” said BoTEC Medical CEO Waldo Shan. “We look forward to building upon our partnership to meet the ever-increasing surgeon demands while improving patient lives.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.